Kare Chemical Technologies provides pharmaceutical-grade CB1 and CB2 receptor ligands and advanced molecular intermediates synthesized through our proprietary catalytic platform.
Our products are available for:
All compounds are manufactured through fully synthetic, catalytically controlled processes.
Receptor Ligands (API-Ready)
Kare synthesizes a diverse library of receptor-targeting ligands designed for consistent pharmaceutical use.
Developing CB1-Selective Ligands
High-affinity central receptor modulators suitable for neurological and pain-related research programs.
Developing CB2-Selective Ligands
Peripheral receptor modulators with applications in inflammation and metabolic regulation.
Developing Dual-Target Ligands
Peripheral receptor modulators with applications in CNS including Epilepsy, anxiety and depression.
Our modular precursor architecture enables rapid generation of structural analogues and optimized variants.
Adjustable molecular architecture for receptor selectivity and pharmacokinetic control.
Enhanced metabolic stability and research applications.
Carbon-13 and other labeled molecules for mechanistic and clinical studies.
These intermediates are:
Kare partners with pharma teams to design and optimize CB1/CB2 ligands, refine selectivity, and scale production, using our catalytic platform to accelerate synthesis and lead optimization.
Access & Licensing
Kare operates under a B2B supply and licensing model. Available through:
